Total Payments
$10,641
2024 Payments
$1,136
Companies
79
Transactions
509
Medicare Patients
6,843
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$10,062 (94.6%)
Education$578.97 (5.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,062 | 498 | 94.6% |
| Education | $578.97 | 11 | 5.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,147 | 58 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $824.36 | 49 | $0 (2024) |
| PFIZER INC. | $634.88 | 40 | $0 (2024) |
| Merck Sharp & Dohme LLC | $525.93 | 27 | $0 (2024) |
| Incyte Corporation | $492.25 | 17 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $438.88 | 25 | $0 (2024) |
| Daiichi Sankyo Inc. | $416.84 | 21 | $0 (2024) |
| Celgene Corporation | $378.54 | 17 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $343.10 | 17 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $268.38 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,136 | 50 | PFIZER INC. ($126.52) |
| 2023 | $1,331 | 57 | Celltrion USA Inc. ($158.50) |
| 2022 | $1,119 | 58 | Incyte Corporation ($156.07) |
| 2021 | $866.47 | 45 | Novartis Pharmaceuticals Corporation ($143.73) |
| 2020 | $935.87 | 46 | E.R. Squibb & Sons, L.L.C. ($166.17) |
| 2019 | $1,884 | 85 | Alexion Pharmaceuticals, Inc. ($268.38) |
| 2018 | $1,715 | 91 | Novartis Pharmaceuticals Corporation ($269.45) |
| 2017 | $1,654 | 77 | Novartis Pharmaceuticals Corporation ($273.75) |
All Payment Transactions
509 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $29.51 | General |
| Category: Oncology | ||||||
| 11/27/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $32.48 | General |
| Category: Hematology | ||||||
| 10/24/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $32.81 | General |
| Category: Oncology | ||||||
| 10/03/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $31.01 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/18/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: Oncology | ||||||
| 09/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $27.78 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: CELLT | ||||||
| 09/06/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $34.72 | General |
| Category: Oncology | ||||||
| 08/27/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.71 | General |
| 08/15/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 08/13/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: IMMUNOLOGY | ||||||
| 08/09/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 08/07/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: Oncology | ||||||
| 07/31/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: DESMOID TUMORS | ||||||
| 07/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $23.11 | General |
| 07/17/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: Oncology | ||||||
| 07/15/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $16.72 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,675 | 49,788 | $938,566 | $393,808 |
| 2022 | 27 | 1,732 | 12,746 | $771,206 | $294,999 |
| 2021 | 30 | 1,872 | 41,588 | $745,835 | $292,203 |
| 2020 | 28 | 1,564 | 8,906 | $596,617 | $207,810 |
Total Patients
6,843
Total Services
113,028
Medicare Billing
$1.2M
Procedure Codes
105
All Medicare Procedures & Services
105 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 31 | 8,640 | $271,814 | $160,314 | 59.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 324 | 810 | $283,500 | $87,574 | 30.9% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 13 | 11,700 | $69,207 | $27,252 | 39.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 117 | 251 | $62,750 | $20,473 | 32.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 15 | 23,250 | $39,525 | $20,266 | 51.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 26 | 157 | $47,100 | $19,197 | 40.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 69 | 69 | $27,600 | $12,940 | 46.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 377 | 992 | $14,880 | $8,333 | 56.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 368 | 1,090 | $16,350 | $8,287 | 50.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 45 | 97 | $14,550 | $5,508 | 37.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $9,300 | $4,554 | 49.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 20 | 155 | $12,480 | $4,052 | 32.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 79 | 284 | $14,200 | $2,939 | 20.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 42 | $12,600 | $2,547 | 20.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 54 | 210 | $10,500 | $2,504 | 23.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 19 | 87 | $21,750 | $2,308 | 10.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 13 | $4,550 | $1,817 | 39.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 21 | 21 | $2,843 | $1,676 | 59.0% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 22 | 173 | $2,621 | $1,103 | 42.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 19 | 1,716 | $446.16 | $164.12 | 36.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 28 | 5,581 | $175,578 | $95,782 | 54.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 314 | 742 | $259,700 | $81,821 | 31.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 113 | 305 | $76,250 | $24,848 | 32.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 32 | 179 | $53,700 | $24,543 | 45.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 87 | 87 | $34,800 | $17,405 | 50.0% |
About Dr. David Dosik, MD
Dr. David Dosik, MD is a Internal Medicine healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770534653.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Dosik, MD has received a total of $10,641 in payments from pharmaceutical and medical device companies, with $1,136 received in 2024. These payments were reported across 509 transactions from 79 companies. The most common payment nature is "Food and Beverage" ($10,062).
As a Medicare-enrolled provider, Dosik has provided services to 6,843 Medicare beneficiaries, totaling 113,028 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 105 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Brooklyn, NY
- Active Since 05/15/2006
- Last Updated 06/11/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1770534653
Products in Payments
- OPDIVO (Biological) $655.06
- KEYTRUDA (Biological) $441.71
- INJECTAFER (Drug) $296.12
- Imbruvica (Drug) $274.81
- ULTOMIRIS (Drug) $268.38
- Lenvima (Drug) $255.65
- TASIGNA (Drug) $248.83
- PROVENGE (Drug) $239.85
- Cabometyx (Drug) $201.87
- IBRANCE (Drug) $195.06
- KISQALI (Drug) $191.95
- MONJUVI (Drug) $179.56
- VEGZELMA (Biological) $158.50
- PROMACTA (Drug) $156.05
- Xofigo (Drug) $155.72
- IMFINZI (Drug) $147.07
- SUTENT (Drug) $146.58
- XTANDI (Drug) $138.17
- TUKYSA (Drug) $135.69
- Pomalyst (Drug) $135.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Brooklyn
Bruce Berger, M.d, M.D
Internal Medicine — Payments: $3.0M
Internal Medicine $3.0M
Dr. Jesi Ramone, Md, MD
Internal Medicine — Payments: $701,491
Internal Medicine $701,491
Dr. Ali El Atat, M.d, M.D
Internal Medicine — Payments: $426,309
Internal Medicine $426,309
Manish Parikh, Md, MD
Internal Medicine — Payments: $360,332
Internal Medicine $360,332
Dr. Samuel Uter, Md, MD
Internal Medicine — Payments: $238,375
Internal Medicine $238,375
Dr. Bharath Reddy, Md, MD
Internal Medicine — Payments: $159,733
Internal Medicine $159,733